title: Toll-like receptor-2 mediates diet and/or pathogen associated atherosclerosis: proteomic findings.
abstract: BACKGROUND
  Accumulating evidence implicates a fundamental link between the immune system and atherosclerosis. Toll-like receptors are principal sensors of the innate immune system. Here we report an assessment of the role of the TLR2 pathway in atherosclerosis associated with a high-fat diet and/or bacteria in ApoE(+/-) mice.
  
  
  RESULTS
  To explore the role of TLR2 in inflammation- and infection-associated atherosclerosis, 10 week-old ApoE(+/-)-TLR2(+/+), ApoE(+/-)-TLR2(+/-) and ApoE(+/-)-TLR2(-/-) mice were fed either a high fat diet or a regular chow diet. All mice were inoculated intravenously, once per week for 24 consecutive weeks, with 50 microl live Porphyromonas gingivalis (P.g) (10(7) CFU) or vehicle (normal saline). Animals were euthanized 24 weeks after the first inoculation. ApoE(+/-)-TLR2(+/+) mice showed a significant increase in atheromatous lesions in proximal aorta and aortic tree compared to ApoE(+/-)-TLR2(+/-) and ApoE(+/-)-TLR2(-/-) mice for all diet conditions. They also displayed profound changes in plaque composition, as evidenced by increased macrophage infiltration and apoptosis, increased lipid content, and decreased smooth muscle cell mass, all reflecting an unstable plaque phenotype. SAA levels from ApoE(+/-)-TLR2(+/+) mice were significantly higher than from ApoE(+/-)-TLR2(+/-) and ApoE(+/-)-TLR2(-/-) mice. Serum cytokine analysis revealed increased levels of pro-inflammatory cytokines in ApoE(+/-)-TLR2(+/+) mice compared to ApoE(+/-)-TLR2(+/-) and TLR2(-/-) mice, irrespective of diet or bacterial challenge. ApoE(+/-)-TLR2(+/+) mice injected weekly for 24 weeks with FSL-1 (a TLR2 agonist) also demonstrated significant increases in atherosclerotic lesions, SAA and serum cytokine levels compared to ApoE(+/-)-TLR2(-/-) mice under same treatment condition. Finally, mass-spectrometry (MALDI-TOF-MS) of aortic samples analyzed by 2-dimensional gel electrophoresis differential display, identified 6 proteins upregulated greater than 2-fold in ApoE(+/-)-TLR2(+/+) mice fed the high fat diet and inoculated with P.g compared to any other group.
  
  
  CONCLUSIONS
  Genetic deficiency of TLR2 reduces diet- and/or pathogen-associated atherosclerosis in ApoE(+/-) mice, along with differences in plaque composition suggesting greater structural stability while TLR-2 ligand-specific activation triggers atherosclerosis. The present data offers new insights into the pathophysiological pathways involved in atherosclerosis and paves the way for new pharmacological interventions aimed at reducing atherosclerosis.
authors.affiliation: Department of Periodontology and Oral Biology, School of Dental Medicine, Boston University, Boston, Massachusetts, United States of America.
authors.forename: Monika
authors.initials: M
authors.lastname: Madan
authors.forename: Salomon
authors.initials: S
authors.lastname: Amar
mesh_terms: D000818:Animals; D001011:Aorta / Q000378:metabolism; D001057:Apolipoproteins E / Q000235:genetics; D050197:Atherosclerosis / Q000378:metabolism*; D002784:Cholesterol / Q000378:metabolism; D004032:Diet; D005947:Glucose / Q000378:metabolism; D007107:Immune System; D007113:Immunity, Innate; D007249:Inflammation; D051379:Mice; D008957:Models, Genetic; D040901:Proteomics / Q000379:methods; D000685:Serum Amyloid A Protein / Q000096:biosynthesis; D051195:Toll-Like Receptor 2 / Q000378:metabolism*
chemical_list: D001057:Apolipoproteins E; D000685:Serum Amyloid A Protein; D051195:Toll-Like Receptor 2; D002784:Cholesterol; D005947:Glucose
references.citation: Am Heart J. 1999 Nov;138(5 Pt 2):S534-6
references.pmid: 10539867
references.citation: Innate Immun. 2008 Feb;14(1):39-49
references.pmid: 18387918
references.citation: J Biol Chem. 2000 Apr 14;275(15):11058-63
references.pmid: 10753909
references.citation: Nat Rev Immunol. 2001 Nov;1(2):135-45
references.pmid: 11905821
references.citation: Circulation. 2004 Jun 8;109(22):2801-6
references.pmid: 15123526
references.citation: Atherosclerosis. 2001 Feb 1;154(2):377-85
references.pmid: 11166770
references.citation: N Engl J Med. 1999 Jan 14;340(2):115-26
references.pmid: 9887164
references.citation: Arterioscler Thromb Vasc Biol. 2000 May;20(5):1262-75
references.pmid: 10807742
references.citation: J Leukoc Biol. 1998 Jun;63(6):650-7
references.pmid: 9620655
references.citation: Nat Med. 2004 Apr;10(4):416-21
references.pmid: 15034566
references.citation: Infect Immun. 2002 Dec;70(12):6658-64
references.pmid: 12438339
references.citation: Atherosclerosis. 2007 Jan;190(1):62-72
references.pmid: 16563401
references.citation: Cardiovasc Res. 2005 Apr 1;66(1):162-9
references.pmid: 15769459
references.citation: Circulation. 2001 Dec 18;104(25):3103-8
references.pmid: 11748108
references.citation: Methods Enzymol. 1996;269:37-41
references.pmid: 8791635
references.citation: Circ Res. 2002 Aug 23;91(4):281-91
references.pmid: 12193460
references.citation: Atherosclerosis. 1999 Dec;147(2):213-25
references.pmid: 10559506
references.citation: Ann Periodontol. 2002 Dec;7(1):72-8
references.pmid: 16013219
references.citation: Circulation. 2000 Dec 19;102(25):3046-52
references.pmid: 11120693
references.citation: Cardiovasc Res. 2000 Feb;45(3):736-46
references.pmid: 10728396
references.citation: Circ Res. 2001 Sep 28;89(7):E41-5
references.pmid: 11577031
references.citation: Int Immunol. 2001 Jul;13(7):933-40
references.pmid: 11431423
references.citation: Circ Res. 1994 Jul;75(1):1-7
references.pmid: 8013067
references.citation: Am Heart J. 1999 Nov;138(5 Pt 2):S419-20
references.pmid: 10539839
references.citation: Atherosclerosis. 2008 Apr;197(2):504-14
references.pmid: 17412346
references.citation: Annu Rev Immunol. 2002;20:197-216
references.pmid: 11861602
references.citation: Infect Immun. 2004 Mar;72(3):1657-65
references.pmid: 14977973
references.citation: J Dermatol Sci. 2004 Apr;34(2):73-82
references.pmid: 15033189
references.citation: J Endotoxin Res. 2000;6(5):393-6
references.pmid: 11521061
references.citation: Cell. 2002 Dec 27;111(7):927-30
references.pmid: 12507420
references.citation: J Exp Med. 1998 Jun 15;187(12):2097-101
references.pmid: 9625770
references.citation: Nature. 2002 Dec 19-26;420(6917):868-74
references.pmid: 12490960
references.citation: J Immunol. 2002 Jul 1;169(1):10-4
references.pmid: 12077222
references.citation: J Clin Invest. 2005 Nov;115(11):3149-56
references.pmid: 16211093
references.citation: Ann N Y Acad Sci. 2001 Dec;947:419-23
references.pmid: 11795305
references.citation: Circulation. 2002 Mar 5;105(9):1135-43
references.pmid: 11877368
references.citation: Circulation. 2000 Apr 18;101(15):1758-9
references.pmid: 10769272
references.citation: EMBO J. 2000 Jul 3;19(13):3325-36
references.pmid: 10880445
references.citation: Atherosclerosis. 2002 Jan;160(1):91-102
references.pmid: 11755926
references.citation: Circulation. 2002 Mar 12;105(10):1158-61
references.pmid: 11889007
references.citation: J Biol Chem. 1999 Nov 19;274(47):33179-82
references.pmid: 10559185
references.citation: Circulation. 2002 Feb 19;105(7):861-7
references.pmid: 11854128
references.citation: Clin Chem. 2001 Mar;47(3):403-11
references.pmid: 11238289
references.citation: Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10679-84
references.pmid: 15249654
references.citation: Arterioscler Thromb Vasc Biol. 2002 May 1;22(5):727-33
references.pmid: 12006383
references.citation: Microbiol Immunol. 2002;46(3):151-8
references.pmid: 12008923
references.citation: Circulation. 2004 Sep 21;110(12):1678-85
references.pmid: 15353494